Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen/Chugai EPO patent case appeal

Executive Summary

Oral arguments were heard Sept. 7 before three-judge federal appeals panel in Washington, D.C. The judges gave no timetable for a ruling. The companies are appealing a Dec. 11 Boston federal court decision that found certain claims of Amgen and Genetics Institute's patents to be invalid but others to be valid. If that decision is upheld, Amgen would be enjoined from selling Epogen unless it allows Chugai on the market, according to an injunction issued in March.
UsernamePublicRestriction

Register

PS018024

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel